Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. infection bacteria
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Infection Bacteria Articles & Analysis

58 news found

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

Infection Control Resources to Identify Shigella and Other Pathogens in Puerto Rico

The Centers for Disease Control and Prevention (CDC) reports there are an estimated 450,000 cases of shigellosis, an infection caused by Shigella bacteria, in the United States each year. ...

ByCochrane & Associates, LLC


Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

The New York State Department of Health (NYSDOH) describes enterococci as part of the normal flora in the intestinal tract and also a common cause of nosocomial infections. The bacteria can also often found in the natural environment, in soil and water. The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly ...

ByCochrane & Associates, LLC


World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

World TB Day and Infection Control Resources in New York City to Help Prevent New Cases

This occurs when people nearby breathe in the bacteria and then become infected. This is why transmission can be a significant risk in healthcare environments and other places where many people share the same space for extended periods of time. ...

ByCochrane & Associates, LLC


Candida auris and Infection Control Resources for Healthcare Facilities in Puerto Rico

Candida auris and Infection Control Resources for Healthcare Facilities in Puerto Rico

CDC reported that this fungus poses a unique challenge to public health because it can cause invasive and often deadly infections that can be resistant to multiple antifungal drugs, and that it is particularly concerning because it can spread to other patients. ...

ByCochrane & Associates, LLC


WHO calls for new innovations to tackle antimicrobial resistance crisis

WHO calls for new innovations to tackle antimicrobial resistance crisis

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection ...

ByOndine Biomedical Inc


Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

About SER-155 SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria ...

BySeres Therapeutics, Inc.


OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

The trial demonstrates that using Unyvero HPN panel in hospitalized pneumonia patients for the examination of bronchoalveolar lavage (BAL) in combination with antibiotic stewardship decreases the duration of inappropriate antibiotic therapy of hospitalized patients with pneumonia at risk for Gram-negative bacteria and supports antibiotic de-escalation in 66% of patients. In this ...

ByOpGen, Inc.


Locus Biosciences Announces $35 Million Financing

Locus Biosciences Announces $35 Million Financing

Through its unique bacteriophage discovery, synthetic biology, and manufacturing platform, Locus is developing two innovative categories of biotherapeutics to address significant unmet medical needs: precision CRISPR-enhanced bacteriophage (crPhage®) products to fight deadly infections, including those caused by multi-drug resistant bacteria; and engineered ...

ByLocus Biosciences, Inc.


Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

About SER-155 SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria ...

BySeres Therapeutics, Inc.


Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

About Pneumococcal Disease Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae (pneumococcus) bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. ...

ByVaxcyte, Inc.


World TB Day and Preventing New Cases in Healthcare Facilities and Correctional Institutions in Puerto Rico

World TB Day and Preventing New Cases in Healthcare Facilities and Correctional Institutions in Puerto Rico

This occurs when people nearby breathe in the bacteria and then become infected. This is why the transmission of tuberculosis can be a significant risk factor in healthcare environments, correctional institutions, and other places where many people are in close proximity for an extended period of time. ...

ByCochrane & Associates, LLC


Preventing Wound Infections and Complications at Urgent Care

Preventing Wound Infections and Complications at Urgent Care

Wounds at Higher Risk to Become Infected Some types of wounds have a higher risk of developing an infection than others. ...

ByKitoTech Medical, Inc.


Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

About Pneumococcal Disease Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae (pneumococcus) bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. ...

ByVaxcyte, Inc.


UVD Robots Joins Ecolab to Fight Hospital Acquired Infections

UVD Robots Joins Ecolab to Fight Hospital Acquired Infections

As new coronavirus variants continue to mutate and spread, the growth in demand for infection prevention solutions using UV-C light is projected to reach $18.94 billion by 2030, witnessing an annual growth rate of 59.7% from 2021 to 2030. Further fueling the demand is the rise in hospital acquired infections (HAIs) that globally cause more fatalities due to the ...

ByBlue Ocean Robotics


UVD Robots Joins Ecolab to Fight Hospital Acquired Infections

UVD Robots Joins Ecolab to Fight Hospital Acquired Infections

As new coronavirus variants continue to mutate and spread, the growth in demand for infection prevention solutions using UV-C light is projected to reach $18.94 billion by 2030, witnessing an annual growth rate of 59.7% from 2021 to 2030. Further fueling the demand is the rise in hospital acquired infections (HAIs) that globally cause more fatalities due to the ...

ByUVD Robots, PART OF BLUE OCEAN ROBOTICS


Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota

Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota

The gut microbiome includes a huge number of bacteria, archaea, fungi, and enteroviruses that colonize the gut. At present, most of the research on gut microbes focuses on the study of bacteria, and with the deepening of research, the number and types of enteroviruses and their impact on human health and disease have received more and more attention. ...

ByCreative Proteomics


The GRAM paper gives face to the AMR crisis - Vaxdyn’s comment about the GRAM paper

The GRAM paper gives face to the AMR crisis - Vaxdyn’s comment about the GRAM paper

The GRAM paper is the most comprehensive study about the global incidence of antibiotic-resistant bacteria. The relevance of this study is that finally gives a clear face, based on data, to the AMR crisis. ...

ByVaxdyn, S. L.


Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

About Pneumococcal Disease Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae (pneumococcus) bacteria. It can result in invasive PD (IPD), including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. ...

ByVaxcyte, Inc.


CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing

CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing

Whole transcriptome sequencing has a wide range of applications, such as growth and development regulation (including animal metamorphosis, plant flowering, fruit development, etc.), environmental adaptation mechanisms (including drought, salt tolerance, disease resistance, etc.), immune interaction (including bacteria, fungus, virus infection). The content of ...

ByCD Genomics


Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test

Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test

Increasing and incorrect antibiotic use leads to antibiotic-resistant bacteria that become more difficult and costly to treat, and more deadly. Today, an estimated 30 percent of antibiotics are inappropriately prescribed to patients because their infections are not obviously bacterial or viral in origin.1 In addition, almost three million Americans each year ...

ByInflammatix, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT